VEGFA and ovarian hyperstimulation syndrome: As a result, the transient increase in Vegf-a expression, which disappeared 8 h after TP4/2 treatment and was associated with a less pronounced increase in ovarian weight compared with hCG, may indicate a low risk of developing OHSS with the use of this low-molecular-weight agonist.